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Safetya b s t r a c t
No therapeutics have been proven effective yet for the treatment of coronavirus disease 2019 (COVID-19)
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To assess the efficacy and
safety of Triazavirin therapy for COVID-19, we conducted a randomized, double-blinded controlled trial
involving hospitalized adult patients with COVID-19. Participants were enrolled from ten sites, and were
randomized into two arms of the study with a ratio of 1:1. Patients were treated with Triazavirin 250 mg
versus a placebo three or four times a day for 7 d. The primary outcome was set as the time to clinical
improvement, defined as normalization of body temperature, respiratory rate, oxygen saturation, cough,
and absorption of pulmonary infection by chest computed tomography (CT) until 28 d after randomiza-
tion. Secondary outcomes included individual components of the primary outcome, the mean time and
proportion of inflammatory absorption in the lung, and the conversion rate to a repeated negative
SARS-CoV-2 nucleic acid test of throat swab sampling. Concomitant therapeutic treatments, adverse
events, and serious adverse events were recorded. Our study was halted after the recruitment of 52
patients, since the number of new infections in the participating hospitals decreased greatly. We random-
ized 52 patients for treatment with Triazavirin (n = 26) or a placebo (n = 26). We found no differences in
the time to clinical improvement (median, 7 d versus 12 d; risk ratio (RR), 2.0; 95% confidence interval
(CI), 0.7–5.6; p = 0.2), with clinical improvement occurring in ten patients in the Triazavirin group and
six patients in the placebo group (38.5% versus 23.1%; RR, 2.1; 95% CI, 0.6–7.0; p = 0.2). All components
of the primary outcome normalized within 28 d, with the exception of absorption of pulmonary infection
(Triazavirin 50.0%, placebo 26.1%). Patients in the Triazavirin group used less frequent concomitant
therapies for respiratory, cardiac, renal, hepatic, or coagulation supports. Although no statistically
significant evidence was found to indicate that Triazavirin benefits COVID-19 patients, our observations
indicated possible benefits from its use to treat COVID-19 due to its antiviral effects. Further study is
required for confirmation.
 2020 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and
Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In 2020, coronavirus disease 2019 (COVID-19) caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dis-
rupted societies around the world. The five most common signs
and symptoms of COVID-19 are fever, cough, fatigue, myalgia,
and dyspnea [1]. While mortality rates are low in healthy people
below 65 years, the elderly and those with comorbidity are far
more prone to serious outcomes, including death [2,3].
Given the lack of effective antiviral therapy against COVID-19,
current treatments mainly focus on symptom and respiratory sup-
port [4]. However, significant efforts have been put into identifying
drugs for the treatment of COVID-19, and chloroquine, remdesivir,
convalescent plasma, and immunoglobulin G transfusion have all
been evaluated, although the effectiveness of any of these agents
has not been proven [5,6].
Triazavirin (TZV), a new antiviral drug, has been on the market
in Russia since 2015. The main principle of action of TZV is to inhi-
bit the synthesis of viral ribonucleic acid (RNA) and the replication
of viral genomic fragments through its synthetic analogue to the
bases of purine nucleosides [7–9]. A phase II clinical trial of TZV
showed that this compound significantly reduces the duration of
the main clinical symptoms of influenza (intoxication, fever, and
respiratory symptoms) and decreases the incidence of influenza-
related complications and the use of symptomatic drugs [10].
However, the efficacy of TZV for COVID-19 is unknown. We con-
ducted a multicenter placebo-controlled trial on this subject.2. Methods
2.1. Study design
We performed a multicenter, double-blinded, randomized con-
trolled trial (RCT) in ten sites in Heilongjiang Province in Northern
China. The study protocol was approved by the institutional review
boards of all local sites, and all participants provided written
informed consent. The study was chaired by a multidisciplinary
steering committee. An independent data and safety monitoring
board (DSMB) monitored the trial following standardized
adverse-event reporting procedures. Independent study monitors
attended all study procedures and verified all recorded data. This
trial is registered on the Chinese Clinical Trial Registry with the
identifier number ChiCTR20000300001 and the study protocol
was recently published [11].
2.2. Ethics
The clinical trial was carried out according to the principles of
the Declaration of Helsinki and followed the laws, regulations,
and administrative provisions of the Health Commission of
Heilongjiang Province. The trial commenced after the approval of
the Ethic Committees was obtained. Participants were informed
of the risks and benefits of the study and were allowed to voluntar-
ily cease participation in the study at any time for any reason. To
protect the privacy of the subjects, each patient was identified with
a unique random number, and patients’ names and personal infor-
mation were kept confidential to everyone except for the
researchers.
2.3. Eligibility criteria
COVID-19 patients were recruited from the emergency depart-
ments, isolation wards, and intensive care unit (ICU) inpatient
departments of the study sites. The inclusion criteria were:
① laboratory-confirmed SARS-CoV-2 infection by real-time reversetranscription polymerase chain reaction (RT-PCR); ② chest com-
puted tomography (CT) imaging-confirmed lung damage—namely,
multiple small plaques and stromal changes in the lungs, mani-
fested in the outer lung, or with multiple ground glass shadows
and infiltration shadows in both lungs (although these changes
might not be present in mild patients); ③ hospitalized patients
with fever (axillary temperature  37.0 C) or respiratory symp-
toms; ④ a time from symptom onset to randomization of less than
12 d; ⑤ not having participated in other clinical research within
the past three months; ⑥ 18 years or older; ⑦ not participating
in other antiviral studies within 28 d of follow-up; and ⑧ written
informed consent. Baseline laboratory, anthropometric, and clini-
cal measurements, including chest CT imaging and throat swab
test by laboratory RT-PCR, were performed at the local sites.
The exclusion criteria were: ① patients who were unsuitable or
who could not participate safely in the study, as judged by the
principle investigators; ② patients with serious grade C liver
disease, according to the Child–Pugh score; ③ patients with
severe renal impairment (glomerular filtration rate  30 mL
(min1.73 m2)1) or continuous renal replacement therapy,
hemodialysis, or peritoneal dialysis; ④ patients with severe ane-
mia (hemoglobin < 60 gL1);⑤ pregnant or breastfeeding women;
⑥ patients with a history of allergy to TZV or its metabolic compo-
nents; ⑦ patients with the possibility of being transferred to
another hospital within 72 h of randomization; and ⑧ patients
who participated in other clinical trials for COVID-19 within 30 d
prior to our screening.
2.4. Randomization and blinding
Randomization, stratified by study site, was based on a
computer-generated allocation sequence; the 1:1 allocation
sequence used permuted, random block sizes of four. The investi-
gators who were responsible for assessing the primary outcomes
and the patients were blinded to the study group assignment.
2.5. Intervention
Participants at each site had their standard treatment supple-
mented with a daily oral dose of the trial drug TZV or its placebo.
Participants with a mild or ordinary condition took 250 mg orally
three times a day (at 9:00, 13:00, and 17:00), respectively, for
seven consecutive days, while participants with a severe or critical
condition took 250 mg orally four times a day (at 9:00, 13:00,
17:00, and 21:00), respectively, for seven consecutive days. A
patient’s condition was considered to be mild/ordinary if symp-
toms such as fever and respiratory tract symptoms were present,
and signs of pneumonia could be seen on imaging. A severe condi-
tion was defined as a respiratory rate  30 breaths per minute,
pulse oxygen saturation (SpO2)  93% on room air at rest state,
arterial partial pressure of oxygen (PaO2)/fraction of inspiration
oxygen (FiO2)  300 mmHg (1 mmHg  133.322 Pa), or > 50%
lesions progression within 24–48 h in pulmonary imaging. A criti-
cal condition was defined as respiratory failure resulting in
mechanical ventilation, shock occurrence, or the occurrence of
other organ failure requiring monitoring and treatment in the ICU.
Drugs were administered by qualified medical or nursing staff.
The first dose of TZV was administered immediately after randomi-
zation. In addition to the study drug or placebo, all patients
received routine standard therapy, according to the Chinese
guidelines for COVID-19 [4,12].
The study drug TZV was manufactured by Zavod Medsintez, Ltd.
(Novouralsk, Russia), and the placebo was manufactured by Tian-
qing Pharmaceutical (High-Tech Development Zone, Harbin,
China). The drug and placebo needed for the study were repack-
aged in identical bottles with the same labels at a Chinese
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medication was stopped and recalled.
The medication period was 7 d, and the clinical symptoms, vital
signs, fingertip oxygen saturation, and adverse events were
recorded every day. Electrocardiograms, blood gas analysis, and
other laboratory tests were performed on days 3 and 7, and CT
was performed on day 7. The follow-up period was 28 d or until
clinical improvement was observed, and the corresponding
examinations were carried out at local hospitals on days 8, 9, 10,
14, 21, and 28 of the follow-up period.
2.6. Sample size calculation
Due to the limited information on TZV for COVID-19 and the
urgent clinical requirements, we expected that enrolling 120
patients in both arms would result in a withdrawal rate due to
death and other unanticipated conditions of less than 20%. After
the recruitment of 52 participants, the DSMB recommended termi-
nating the trial because no more daily new cases were added for a
continuous week.
2.7. Statistical analysis
Categorical variables are described as counts and percentages,
and continuous variables are expressed as median, interquartile
range (IQR) values, mean, and standard deviation. Proportions for
the categorical data were compared using the v2 test or Fisher’s
exact test. Means for continuous data were compared using inde-
pendent group t-tests if the data were normally distributed; other-
wise, the Mann–Whitney U test was used. No imputation was
made for missing data.
A Cox proportional hazard ratio model was used to determine
whether there were differences in the alleviation of symptoms.
For unadjusted comparisons, a two-sided significant level (a) of
less than 0.05 was considered statistically significant. The analyses
were not adjusted for multiple comparisons. All statistical analyses
were performed using the SAS software (version 9.4).
2.8. Outcomes
2.8.1. Primary outcome
The primary endpoint was time to clinical improvement,
defined as the days from randomization until normalization.
Clinical improvement was assessed by five components including
body temperature, respiratory rate, oxygen saturation, alleviation
of cough, and absorption of pulmonary infection by chest CT.
Normalization was defined as body temperature < 37.0 C,
respiratory rate < 24 times per minute indoors, and oxygen
saturation > 94% (fingertip). Alleviation of cough was defined as a
reduced severity of cough from a physician-reported scale of
severe or moderate to mild condition or absence. Absorption of
pulmonary infection was defined as an absorption area > 2/3 by
Digital Imaging and Communications in Medicine (DICOM) images
on chest CT. Alleviation of these five clinical symptoms were
required to stay normal for at least 72 h on all components to fulfill
the primary endpoint of clinical improvement.
2.8.2. Secondary outcomes
Prespecified secondary outcomes included clinical improve-
ment rate, median time and proportion of defervescence, mean
time and proportion of significant inflammatory absorption of lung
lesions, a negative conversion rate of the viral nucleic acid test,
mortality at day 28, and the conversion from mild or ordinary to
severe or critical severe status. The diagnosis and classification of
mild, ordinary, severe, and critical severe conditions of this disease
were set according to Chinese guidelines for COVID-19 [4,12].Defervescence time was defined as the days from randomiza-
tion to a temperature less than 37.0 C maintained for at least 24
or 72 h. A throat swab viral nucleic acid test was repeated after
48 h following a negative test result. The conversion rate in severe
and critical severe subjects was assessed with a six-point scale. The
patient being discharged from the hospital or the score decreasing
by two points from the baseline was considered to be conversion.
2.8.3. Exploratory outcomes
The exploratory outcomes were changes in laboratory indica-
tors, including routine blood test, C-reactive protein (CRP), coagu-
lation function, myocardial enzymes, and hepatic and renal
functions. The recovery rates of the above indicators from abnor-
mal to normal were also calculated.3. Results
During the study period, we screened 245 patients, of which
111 were eligible and 68 signed informed consent. A total of 52
patients with COVID-19 and laboratory-confirmed infection under-
went randomization (Fig. 1). The first participant was enrolled on
14 February 2020, and the trial ended on 6 March 2020. The trial
was terminated ahead of schedule by the decision of the DSMB
because the COVID-19 outbreak in China was under control at
the time, and there had been no new cases for one week.
Among the 52 patients, 26 were assigned to the TZV group and
26 to the placebo group. The most frequent comorbidities were
hypertension (28.8%), cardiovascular disease (15.4%), diabetes
(15.4%), cerebrovascular disease (7.7%), and chronic obstructive
pulmonary disease (COPD) (5.8%). Seven patients (26.9%) in the
TZV group and four patients (15.4%) in the placebo group discon-
tinued taking drugs varying from the second day to the sixth day
of the study. The reasons for discontinued intervention are listed
in Fig. 1. All participants were included in the intention-to-treat
analysis.
Baseline characteristics are shown in Tables 1 and S1 of Appen-
dix A. The median age of the patients was 58 years (IQR, 48–
65 years), and 50% were male. The median interval time between
symptom onset and randomization was 7 d (IQR, 5–10 d). The most
common four signs and symptoms were dry cough (55.8%), nasal
obstruction (38.5%), pharyngalgia (32.7%), and fever (28.8%).
Among the 52 patients, 44 (84.6%) had abnormalities on chest
CT, 30 (57.7%) had bilateral patchy ground glass shadow, 18
(34.6%) had consolidation, and two had pleural effusion (3.9%).
3.1. Primary outcome
The time to clinical improvement was 7 d after TZV versus 12 d
after placebo (risk ratio (RR), 2.0; 95% confidence interval (CI), 0.7–
5.6; p = 0.2; Table 2).
3.2. Secondary outcomes
Clinical improvement was observed in ten patients of the TZV
group and six patients of the placebo group in the intention-to-
treat population (38.5% versus 23.1%; RR, 2.1; 95% CI, 0.6–7.0;
p = 0.2) (Fig. 2(a), Table 2). In patients whose body temperature
was maintained at < 37 C for 24 or 72 h, the rate of deferves-
cence in the TZV group was higher than that in the placebo group
(100% versus 80%, p = 0.5; 87.5% versus 70.0%, p = 0.6), and the
median time to defervescence was 45.5 h versus 52.0 h, with
p = 1.0 (for 24 h) and 4.5 d versus 6.0 d, with p = 0.7 (for 72 h),
respectively.
The median time to absorption of pulmonary infection was 10 d
versus 12 d (RR, 2.0; 95% CI, 0.7–5.5; p = 0.2; Table 2, Fig. 2(b)). Ten
Table 1
Demographics and baseline clinical characteristics of the patients.
Characteristics Total (n = 52) TZV group (n = 26) Placebo group (n = 26)
Demographic features
Age (year), median (IQR) 58 (48–65) 53 (46–62) 59 (51–69)
Male sex, number (percentage) 26 (50.0%) 14 (53.9%) 12 (46.1%)
Smoker, number (percentage) 6 (11.5%) 4 (15.4%) 2 (7.7%)
Heart rate (bpm), median (IQR) 81 (75–90) 83 (79–90) 80 (70–86)
Respiratory rate (times per minute), median (IQR) 20 (19–20) 20 (18–20) 20 (19–21)
Mean arterial pressure (mmHg), median (IQR) 99 (90.5–105.5) 96 (86.5–104.5) 99 (97–111)
Fever on admission, number (percentage) 15 (28.8%) 7 (26.9%) 8 (30.8%)
Days from illness onset to randomization, median (IQR) 7 (5–10) 8 (5–11) 5.5 (4–8)
Radiologic findings, number (percentage)
Abnormalities on chest CT 44 (84.6%) 21 (80.8%) 23 (88.5%)
Hydrothorax 2 (3.9%) 0 (0) 2 (7.7%)
Consolidation 18 (34.6%) 6 (23.1%) 12 (46.2%)
Laboratory findings, median (IQR)
White blood cell count (109 L1) 6.0 (4.1–7.4) 6.1 (3.8–8.6) 5.8 (4.4–6.9)
Distribution, number (percentage)
< 4 13 (25.0%) 8 (30.8%) 5 (19.2%)
4–10 34 (65.4%) 15 (57.7%) 19 (73.1%)
> 10 5 (9.6%) 3 (11.5%) 2 (7.7%)
Neutrophil count (109 L1) 3.9 (2.7–5.9) 4.0 (2.5–6.0) 3.8 (2.9–5.3)
Monocyte count (109 L1) 0.4 (0.3–0.6) 0.4 (0.3–0.6) 0.4 (0.3–0.5)
Lymphocyte count (109 L1) 1.4 (1.0–1.9) 1.6 (1.0–2.2) 1.2 (1.0–1.8)
Distribution, number (percentage) 30 (57.7%) 13 (50.0%) 17 (65.4%)
< 1.5
Platelet count (109 L1) 203.0 (168.0–252.0) 198.0 (168.0–246.0) 207.5 (169.5–270.0)
Distribution, number (percentage)
< 150 10 (19.2%) 6 (23.1%) 4 (15.4%)
Hemoglobin (gL1) 135.5 (126.0–155.0) 135.0 (127.0–151.0) 138.5 (124.0–157.0)
PT (s) 11.5 (11.0–13.0) 11.5 (11.0–13.3) 11.5 (10.8–12.4)
APTT (s) 29.1 (27.5–31.4) 29.0 (27.1–33.5) 29.1 (27.6–31.0)
D-dimer (lgL1) 0.5 (0.3–1.0) 0.5 (0.2–1.0) 0.4 (0.3–1.0)
CRP (mgL1) 5.0 (5.0–15.0) 9.0 (5.0–14.5) 5.0 (5.0–20.8)
Procalcitonin (ngml1) 0.10 (0.09–0.11) 0.10 (0.09–0.10) 0.10 (0.10–0.12)
LDH (lgL1) 194.0 (163.0–247.0) 175.0 (163.0–237.0) 200.0 (164.0–303.5)
Creatine kinase (lgL1) 58.0 (40.0–92.0) 54.0 (35.0–92.0) 59.8 (41.0–81.8)
CK-MB (lgL1) 12.0 (8.9–14.8) 12.0 (8.9–15.0) 12.0 (8.5–14.5)
a-HBDH (lgL1) 145.0 (116.0–183.0) 132.5 (119.0–153.0) 158.0 (112.0–194.0)
ALT (lgL1) 22.3 (14.0–32.0) 22.7 (14.0–33.0) 22.0 (14.0–26.1)
AST (lgL1) 20.0 (16.0–25.0) 19.7 (16.7–25.0) 21.0 (16.0–28.7)
Total bilirubin (lmolL1) 12.1 (9.2–17.4) 13.2 (11.1–20.3) 9.6 (6.3–15.3)
Blood urea nitrogen (lmolL1) 4.2 (3.4–5.5) 4.2 (3.4–5.6) 4.2 (3.9–5.1)
Creatinine (lmolL1) 63.0 (51.7–73.0) 64.1 (51.7–73.0) 59.6 (52.0–66.7)
Lymphocytopenia is defined as a lymphocyte count of less than 1.5 per cubic liter. Thrombocytopenia is defined as a platelet count of less than 150 per cubic liter.
bpm: beat per minute; PT: prothrombin time; APTT: activated partial thromboplastin time; LDH: lactate dehydrogenase; CK-MB: creatine kinase–MB; a-HBDH: a-
hydroxybutyrate dehydrogenase; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
Fig. 1. Flow diagram of participants in the trial.
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Table 2
Clinical outcomes in the intention-to-treat population.








Time to clinical improvement (d)a, median (IQR) 11.0 (7.0–15.5) 7.0 (6.0–15.0) 12.0 (7.0–16.0) 2.0 (0.7–5.6) 0.2
Secondary outcomes
Patients with clinical improvement, number (percentage) 16 (30.8%) 10 (38.5%) 6 (23.1%) 2.1 (0.6–7.0%) 0.2
Normalization of body temperature (< 37.0 C)
Maintained at least 72 h
Time from randomization to normal body temperature (d), median (IQR) 5.5 (4.0–8.0) 4.5 (4.0–9.5) 6.0 (5.0–8.0) 1.2 (0.4–3.6) 0.7
Patients with normal body temperature, number (percentage) 14/18 (77.8%) 7/8 (87.5%) 7/10 (70.0%) 3.0 (0.2%–36.3%) 0.6
Maintained at least 24 h
Time from randomization to normal body temperature (h), median (IQR) 47.0 (43.0–72.0) 45.5 (40.0–81.5) 52.0 (46.0–72.0) 1.1 (0.4–3.2) 1.0
Patients with normal body temperature, number (percentage) 16/18 (88.9%) 8/8 (100.0%) 8/10 (80.0%) NAb 0.5
The severity of cough alleviated to mildness or absence
Time from randomization to mildness or absence (d), median (IQR) 6.0 (6.0–8.5) 6.0 (6.0–11.0) 6.0 (6.0–6.0) NA 0.7
Patients with mild cough or absence, number (percentage) 4/4 (100.0%) 3/3(100.0%) 1/1(100.0%) NA 1.0
Normalization of respiratory rate ( 24 times per minute)
Time from randomization to normal respiratory rate (d), median (IQR) 10.5 (10.5) 10.0 (10.0) 11.0 (11.0) NA 1.0
Patients with normal respiratory rate, number (percentage) 2/2 (100.0%) 1/1(100.0%) 1/1(100.0%) NA 1.0
Normalization of oxygen saturation (> 94%)
Time from randomization to normal oxygen saturation (d), median (IQR) 4.0 (4.0) 4.0 (4.0) 4.0 (4.0) NA 1.0
Patients with normal oxygen saturation, number (percentage) 3/3(100.0%) 1/1(100.0%) 2/2 (100.0%) NA 1.0
Obvious absorption of pulmonary infectionc
Time from randomization to obvious absorption of pulmonary infection
(d), median (IQR)
11.0 (7.0–15.0) 10.0 (6.0–15.5) 12.0 (7.0–14.0) 2.0 (0.7–5.5) 0.2
Patients with obvious absorption of pulmonary infection, number (percentage) 16/43 (37.2%) 10/20 (50.0%) 6/23 (26.1%) 2.8 (0.8%–10.2%) 0.1
Patients with negative RT-PCR for viral nucleic acidd 45 (86.5) 24 (92.3) 21 (80.8) 2.9 (0.5–16.3) 0.4
Day 28 mortality, number (percentage) 1 (1.9%) 0 1 (3.9%) NA 1.0
Conversion rate of severe and critical conditione, number (percentage) 6/7 (85.7%) 3/3 (100.0%) 3/4 (75.0%) NA 1.0
a Time to clinical improvement is defined as the number of days from randomization until normalization of the five points of body temperature, respiratory rate, oxygen
saturation at the fingertip, alleviation of cough, and obvious absorption of pulmonary infection by chest CT, whichever came last. Normalization of body temperature is
defined as a temperature less than 37.0 C. A respiratory rate less than 24 times per minute is considered normal, and the oxygen saturation should be greater than 94%.
Alleviation of cough is defined as the severity of cough changing to mildness or absent on a physician-reported scale of severe, moderate, mild, and absent. Obvious
absorption of pulmonary infection is defined as an absorption area of more than 2/3 of the lesions by DICOM images on chest CT. All five points should be maintained at
normal levels for at least 72 h.
b NA means not applicable.
c Obvious absorption of pulmonary infection is defined as an absorption area of more than 2/3 of the lesions by DICOM images on chest CT. DICOM image data from each
site were uploaded to the imaging center of the First Affiliated Hospital of Harbin Medical University, and the final analysis was made by a pre-selected expert panel according
to the unified standards.
d The throat swab viral nucleic acid test was repeated after 48 h if its result converted to negative.
e The conversion rate in severe and critical patients was assessed on a six-point scale. The patient being discharged from the hospital or the score decreasing by two points
from baseline was considered to be conversion.
Fig. 2. The survival curves for clinical improvement, obvious absorption of pulmonary infection and the time of negative conversion of the viral nucleic acid test. (a) The
survival curve with proportion of clinical improvement; (b) the obvious absorption of pulmonary infection by chest CT imaging; (c) the proportion with repeated negative
viral nucleic acid test in 48 h by RT-PCR.
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demonstrated significant absorption of pulmonary infection
(50.0% versus 26.1%, RR, 2.8; 95% CI, 0.8–10.2; p = 0.1). The
negativity conversion rate from a positive COVID-19 nucleic acid
test to a negative result was 92.3% versus 80.8%, with p = 0.4
(Table 2, Fig. 2(c)). One patient who had been randomly assigned
to the placebo group died over the course of the study (Table 2).
There was no significant difference in the conversion rate fromsevere and critical condition to mild or ordinary condition between
the two groups (100.0% versus 75.0%, p = 1.0).
3.3. Safety outcomes
Adverse events were reported to be lower in six patients (23.1%)
in the TZV group relative to ten (38.5%) in the placebo group
(Table 3). Nausea and vomiting (11.5%), hypoalbuminemia (3.8%),
Table 3
Adverse events, serious adverse events, and concurrent treatment.
Outcome Number (percentage (%)) p value
Total (n = 52) TZV group (n = 26) Placebo group (n = 26)
Adverse events 16 (30.8) 6 (23.1) 10 (38.5) 0.2
Nausea and vomiting 3 (5.8) 3 (11.5) 0 0.2
Anemia 3 (5.8) 0 3 (11.5) 0.2
Diarrhea 2 (3.8) 0 2 (7.7) 0.5
Hypokalemia 2 (3.8) 0 2 (7.7) 0.5
Sour regurgitation and abdominal discomfort 1 (1.9) 1 (3.8) 0 1.0
Hypoalbuminemia 1 (1.9) 1 (3.8) 0 1.0
Granulocytopenia 1 (1.9) 1 (3.8) 0 1.0
Electrolyte disturbance 1 (1.9) 1 (3.8) 0 1.0
Hypoproteinemia 1 (1.9) 0 1 (3.8) 1.0
Dizziness 1 (1.9) 0 1 (3.8) 1.0
Whole body discomfort and chest tightness 1 (1.9) 0 1 (3.8) 1.0
Urinary tract infection 1 (1.9) 0 1 (3.8) 1.0
Serious adverse events 9 (17.3) 4 (15.4) 5 (19.2) 1.0
Death 1 (1.9) 0 1 (3.9) 1.0
Admission to ICU 6 (11.5) 3 (11.5) 3 (11.5) 1.0
Acute hepatic injury 2 (3.9) 1 (3.9) 1 (3.9) 1.0
Arrhythmia (paroxysmal atrial fibrillation) 1 (1.9) 1 (3.9) 0 1.0
Concurrent treatments 41 (78.9) 21 (80.8) 20 (76.9) 0.7
Antimicrobial drugs 36 (69.2) 18 (69.2) 18 (69.2) 1.0
Antiviral drugs 36 (69.2) 18 (69.2) 18 (69.2) 1.0
Interferon 34 (65.4) 16 (61.5) 18 (69.2) 0.6
Arbidol 32 (61.5) 16 (61.5) 16 (61.5) 1.0
Ribavirin 15 (28.9) 7 (26.9) 8 (30.8) 0.8
Lopinavir 5 (9.6) 3 (11.5) 2 (7.7) 0.6
Antibacterial drugs 25 (48.1) 11 (42.3) 14 (53.8) 0.4
Hydroxychloroquine 14 (26.9) 5 (19.2) 9 (34.6) 0.2
Antifungal drugs 3 (5.8) 1 (3.8) 2 (7.7) 0.6
Chinese medicine therapy 33 (63.5) 17 (65.4) 16 (61.5) 0.8
Chinese patent medicine 18 (34.6) 6 (23.1) 12 (46.2) 0.1
Decoction 10 (19.2) 6 (23.1) 4 (15.4) 0.5
Injection 14 (26.9) 8 (30.8) 6 (23.1) 0.5
Glucocorticoid therapy 23 (44.2) 10 (38.5) 13 (50.0) 0.4
Immune regulation therapy 19 (36.5) 10 (38.5) 9 (34.6) 0.8
Oxygen therapy 15 (28.8) 5 (19.2) 10 (38.5) 0.2
Antihypertensive drugs 11 (21.2) 3 (11.5) 8 (30.8) 0.1
Nonsteroidal anti-inflammatory drugs 7 (13.5) 2 (7.7) 5 (19.2) 0.4
Blood volume expander 7 (13.5) 3 (11.5) 4 (15.4) 1.0
Antiplatelet drugs 7 (13.5) 2 (7.7) 5 (19.2) 0.4
Anticoagulants drugs 5 (9.6) 2 (7.7) 3 (11.5) 1.0
Dilating blood vessels to improve microcirculation 3 (5.8) 1 (3.9) 2 (7.7) 1.0
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regurgitation and abdominal discomfort (3.8%) were reported in
the TZV group, while anemia (11.5%), diarrhea (7.7%), and hypoka-
lemia (7.7%) appeared in the placebo group.
Serious adverse events occurred in a total of nine patients, with
four events in the TZV group and five events in the placebo group.
One patient in the TZV group developed arrhythmia after taking
the study drug. One death occurred in the placebo group, while
nobody in the TZV group died. The patient who died during the
trial was a 70-year-old man; his condition worsened on the day
of enrollment, with his blood oxygen saturation dropping down
to 83%. Upon adjusting the flow rate of oxygen to 7 Lmin1, his
blood oxygen saturation was maintained at 90% and his oxygena-
tion index was less than 300 mmHg. Chest CT examination
revealed a serious chest inflammation with 75% pulmonary sha-
dow. The patient was transferred to the ICU the day after the
enrollment day, and his condition continued to worsen with the
development of severe respiratory and circulatory failure. The
patient died on the third day after randomization (Table 3).4. Discussion
Our randomized trial found that the combination of TZV and
standard therapy was not associated with a statistically significant
overall improvement of the clinical outcomes for patients withCOVID-19 relative to a placebo. Such a negative result might be
ascribed at least partly to the small sample size enrolled in the
study.
A strength of this trial is that it was an add-on interventional
study consistingof the Chinese standard therapyplus the studydrug
or placebo. This design ensuredprotocol compliance andmaximized
the enrollment of patients in this trial. There are also limitations.
First, all assessmentsof clinical symptomsandsignswere conducted
by local investigators, who were primarily engaged in the emergent
clinical affairs and who did not have trial Standard Operation
Procedure training ahead of time. Second, no central laboratory
was available for rapid and timely testing or themonitoring of every
patient for sample shipping biosafety. Third, the sample size of our
RCT was small. Because the RCT was designed and carried out in
Heilongjiang Province andCOVID-19 is a time-limiteddisease in this
region of China, there were not enough newly infected patients for
our trial with the planned sample size.
In terms of the overall efficacy of TZV in our study, the percent-
age of patients with clinical improvement in the TZV group was
nearly twice as high as that in the placebo group, and the median
time to clinical improvement was five days shorter with TZV than
with a placebo. The rates of stable defervescence maintained for 24
and 72 h were both higher in the TZV group than in the placebo
group. In fact, by the end of the follow-up period, the body tempera-
ture, respiratory rate, oxygen saturation, and cough recovered to
normal in all participants, with the exception of the slow
X. Wu et al. / Engineering 6 (2020) 1185–1191 1191absorption of pulmonary infection as shown by chest CT. Further-
more, the beneficial effects of TZV were associated with a higher
recovery rate of abnormal neutrophil percentage, lymphocyte
count, and lymphocyte percentage in routine blood tests, and a
higher serum level of CRP (Table S2). These results were consistent
with reduced concurrent usage of antibacterial drugs, hydroxy-
chloroquine, antifungal drugs, glucocorticoids, and non-steroid
anti-inflammatory drugs for fever control (Tables 3 and S3).
The essential manifestation of clinical symptoms in COVID-19
patients comprises infection by SARS-CoV-2 and the development
of pneumonia. As for the antiviral effect, the conversion rate of the
negative virus test reached 92.3% in the TZV group, which was 10%
higher than that in the placebo group. A higher absorption rate and
a shorter absorption time in pulmonary CT in the TZV group indi-
cated a reduction in the lower inflammatory lesions in the lung after
treatment with antiviral agents. Moreover, less frequent usages of
ordinary oxygen support and anti-tussive/anti-asthmatic/expector
ant drugs to control symptoms occurred in the TZV group, demon-
strating the beneficial effects of TZV on respiratory symptoms.
TZV treatment yielded higher recovery rates of abnormal serum
levels of bilirubin, indirect bilirubin, total protein, albumin, and uric
acid, as well as less usage of electrolyte solution and diuretics, indi-
cating less damage in hepatic and renal functions. A high level of
plasma fibrinogen is an important risk factor in the hypercoagulable
state. Elevated D-dimer in the early stage of COVID-19 is closely
related to the inflammatory response, while a sharp rise in D-dimer
accompanied by respiratory failure suggests the possible generation
of a ‘‘cytokine storm.” In this study, the recovery rate ofD-dimer after
TZV treatment reached 20.0%, while the recovery rate was 0 in the
placebo group. Furthermore, the beneficial effect of TZV was mani-
fested by less usage of antiplatelet and anticoagulant drugs.
In this study, the recovery rate of lactate dehydrogenase (LDH)
was nearly twice as high in the TZV group as in the placebo group.
A previously case study showed that cardiac damage is an impor-
tant complication associated with COVID-19, even in patients
without symptoms or signs of pneumonia [13]. Furthermore, TZV
treatment was associated with less frequent usage of blood volume
expanders, antihypertensive drugs, and drugs for dilating blood
vessels to improve microcirculation in the TZV group. Thus, TZV
may benefit COVID-19 patients by reducing cardiac damage. In
summary, TZV may be beneficial in pulmonary, cardiac, renal,
hepatic, and coagulable functions in patients with COVID-19 due
to its antiviral properties. Larger studies are needed to confirm or
refute these observations.
5. Conclusions
In this pilot trial, TZV showed potential for treating COVID-19
due to its antiviral effects by generally reducing inflammatory
reactions and thus reducing damage to vital organs and reducing
the need for therapeutic support.
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